Stephen J. Greene, Javed Butler,
... 0.48 (95% CI, 0.20–1.20) PONTIAC (NCT00562952)Randomized, controlled trial of treatment in cardiac ... pro–B-type natriuretic peptide; OR, odds ratio; PONTIAC, NT-proBNP Guided Primary Prevention of CV Events ... AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squib, CVRx, G3 Pharmacautical, Innolife, Janssen, Luitpold, Medtronic, Merck, Novartis, Relypsa, ...
Tópico(s): Cardiovascular Function and Risk Factors
2019 - Lippincott Williams & Wilkins | Circulation